Leap Therapeutics, Inc. 是一家临床阶段的生物制药公司,致力于开发用于治疗癌症患者的新型疗法。公司总部位于马萨诸塞州剑桥市,目前拥有52名全职员工。该公司于2017年1月24日上市。该公司致力于开发针对生物标志物的新型抗体疗法,旨在通过抑制肿瘤发生发展的关键通路来治疗癌症患者。公司目前处于临床阶段的主要药物候选产品是sirexatamab(DKN-01),这是一种抑制Dickkopf相关蛋白1(DKK1)的单克隆抗体。DKK1也是CKAP4/PI3K/AKT信号通路的调节因子。该公司正在开展DKN-01在结直肠癌患者中的临床试验,同时也已在胃癌/胃食管交界处癌以及子宫内膜癌患者中进行了临床试验。此外,公司还拥有一项临床前项目,用于开发一种名为FL-501的专有单克隆抗体。FL-501是一种处于临床前研发阶段的单克隆抗体,靶向生长分化因子15(GDF15),该因子是一种细胞因子,在多种应激条件下会产生较高水平。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CYPH. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CYPH is a Sell candidate.
CYPH stock price ended at $0.6 on 星期四, after dropping 3.23%
On the latest trading day Feb 12, 2026, the stock price of CYPH fell by 3.23%, dropping from $0.59 to $0.60. During the session, the stock saw a volatility of 10.53%, with prices oscillating between a daily low of $0.57 and a high of $0.63. On the latest trading day, the trading volume for CYPH decreased by 990.3K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.1M shares were traded, with a market value of approximately $33.9M.